Yahoo
NasdaqCM - Nasdaq Real Time Price USD

SCYNEXIS, Inc. (SCYX)

5.16 -0.07 (-1.34%)
As of 11:52:50 AM EDT. Market Open.
Chart Range Bar
Loading chart for SCYX
  • Previous Close 5.23
  • Open 5.33
  • Bid 3.75 x 200
  • Ask 6.55 x 200
  • Day's Range 5.11 - 5.34
  • 52 Week Range 3.53 - 10.48
  • Volume 37,295
  • Avg. Volume 137,912
  • Market Cap (intraday) 51.34M
  • Beta (5Y Monthly) 1.10
  • PE Ratio (TTM) --
  • EPS (TTM) -0.91
  • Earnings Date (est.) Nov 4, 2026
  • Forward Dividend & Yield --
  • Ex-Dividend Date --
  • 1y Target Est 36.55

SCYNEXIS, Inc., a biotechnology company, engages in drug development for the treatment and prevention of difficult-to-treat and drug-resistant fungal infections in the United States. The company offers BREXAFEMME for the treatment of patients with vulvovaginal candidiasis and for the reduction in the incidence of recurrence. It also develops SCY-247, which is in Phase I clinical trial for the treatment of invasive fungal infections. The company was formerly known as SCYNEXIS Chemistry & Automation, Inc. and changed its name to SCYNEXIS, Inc. in June 2002. SCYNEXIS, Inc. was incorporated in 1999 and is headquartered in Jersey City, New Jersey.

www.scynexis.com

18

Full Time Employees

December 31

Fiscal Year Ends

Healthcare

Sector

Performance Overview

Trailing total returns as of 9/1/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .

YTD Return

SCYX
2.06%
S&P 500 (^GSPC)
11.94%

1-Year Return

SCYX
22.38%
S&P 500 (^GSPC)
18.61%

3-Year Return

SCYX
82.30%
S&P 500 (^GSPC)
69.69%

5-Year Return

SCYX
89.86%
S&P 500 (^GSPC)
69.38%

Earnings Trends

View More

Earnings Per Share

GAAP
Normalized
GAAP
Normalized

Revenue vs. Earnings

Annual
Quarterly
Annual
Quarterly
Q1 FY26
Revenue --
Earnings -21.3M
Profit Margin 0.00%

Q3

FY25

Q4

FY25

Q1

FY26

-20M
-10M
0
10M
-2500.0%
-2000.0%
-1500.0%
-1000.0%
-500.0%
0.0%

Analyst Insights

View More

Analyst Price Targets

32.00
36.55 Average
5.16 Current
44.64 High

Analyst Recommendations

  • Strong Buy
  • Buy
  • Hold
  • Underperform
  • Sell

Latest Rating

Date 8/13/2026
Analyst Guggenheim
Rating Action Maintains
Rating Buy
Price Action Raises
Price Target 24 -> 33

Statistics

View More

Valuation Measures

Annual
As of 8/27/2026
  • Market Cap

    54.37M

  • Enterprise Value

    2.24M

  • Trailing P/E

    --

  • Forward P/E

    3.72

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    2.19

  • Price/Book (mrq)

    0.81

  • Enterprise Value/Revenue

    0.12

  • Enterprise Value/EBITDA

    --

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    -53.26%

  • Return on Assets (ttm)

    -20.82%

  • Return on Equity (ttm)

    -18.38%

  • Revenue (ttm)

    19.22M

  • Net Income Avi to Common (ttm)

    -10.23M

  • Diluted EPS (ttm)

    -0.91

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    54.08M

  • Total Debt/Equity (mrq)

    2.91%

  • Levered Free Cash Flow (ttm)

    -7.32M

Compare

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Company Insights

Fair Value

5.16 Current

Dividend Score

0 Low
Sector Avg.
100 High

Hiring Score

0 Low
Sector Avg.
100 High

Insider Sentiment Score

0 Low
Sector Avg.
100 High

People Also Watch

Mobilize your Website
View Site in Mobile | Classic
Share by: